MedTrace Logo

Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer

NCT01238029 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2014-11-21

No results posted yet for this study

Summary

The purpose of the study is to investigate safety and efficiency of the triple combination of capecitabine, lapatinib and vinorelbine in patients with metastatic breast cancer.

Conditions

Interventions

DRUG

Lapatinib and Capecitabine and Vinorelbine

Dose finding Study Lapatinib: 1000-1250 oral, once daily, days 1-21 Capecitabine: 1000 mg/sqm oral, bid, days 1-14 Vinorelbine 10-22,5 mg/sqm, i.v. Day 1 + 8

Sponsors & Collaborators

  • iOMEDICO AG

    collaborator INDUSTRY

  • Arbeitsgemeinschaft fur Internistische Onkologie

    collaborator OTHER

  • Arbeitskreis Klinische Studien

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Sponsor GmbH

    lead OTHER

Principal Investigators

  • Ulrike Soeling, MD · Goethestr. 47, 34119 , Kassel, Germany

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01238029 on ClinicalTrials.gov